David Dean, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Little Rock, ARNPI 1790744811
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,373 of the $7,644 with a category attached, or 70.3%. It is spread thinly across 30 manufacturers, the largest accounting for just 21.6%. Reporting peaked in 2024 at $2,470 and has fallen 73.2% since, to $662 in 2025.
Across 205 payments — averaging $37.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$2K
- Smith+Nephew$2K
- Paratek Pharmaceuticals, Inc.$693
- Integra Lifesciences Corporation$602
- KCI USA, Inc.$480
- Biotissue Holdings Inc.$385
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$1202%
- Travel & lodging$2,14628%
- Food & beverage$5,37370%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 5 | $1,649 |
| Smith+Nephew | 97 | $1,567 |
| Paratek Pharmaceuticals, Inc. | 23 | $693 |
| Integra Lifesciences Corporation | 4 | $602 |
| KCI USA, Inc. | 12 | $480 |
| Biotissue Holdings Inc. | 2 | $385 |
| Johnson & Johnson | 9 | $376 |
| AbbVie(2 entities) | 11 | $292 |
| Kerecis Limited | 5 | $254 |
| Organogenesis Inc. | 3 | $206 |
| Solventum Corporation | 4 | $174 |
| Averitas Pharma Inc. | 2 | $130 |
| Shionogi Inc | 2 | $127 |
| Melinta Therapeutics, LLC | 6 | $123 |
| Misonix Inc | 1 | $120 |
| Hollister Incorporated | 1 | $89 |
| Amniox Medical, Inc. | 1 | $75 |
| Merck | 4 | $65 |
| Coloplast | 1 | $31 |
| Cashflow Solutions, LLC | 2 | $30 |
| TEI Medical Inc. | 1 | $28 |
| Tactile Systems Technology Inc | 1 | $25 |
| Advanced Oxygen Therapy Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Urgo Medical North America, LLC | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Nevro Corp. | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Osiris Therapeutics Inc. | 1 | $11 |
| Aroa Biosurgery Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTEGRA MESHED BILAYER WOUND MATRIX$509
- INTEGRA WOUND MATRIX (IWM)$509
- PRIMATRIX$509
- INTEGRA DERMAL REGENERATION TEMPLATE$509
- INTEGRA FLOWABLE WOUND MATRIX$509
- Kerecis SurgiClose$480
- Prokera$278
- AmnioGraft$278
- AmnioGuard$278
- NUZYRA$125
- Kerecis GraftGuide$120
- TheraSkin$120
- Santyl$119
- REGRANEX$119
- Oasis$119
- V.A.C. DERMATAC$114
- DALVANCE$112
- ACTIV.A.C.$112
- XARELTO$112
- Fetroja$109
How this compares
$7,644 in reported general payments places this provider in the 65th percentile of 48 thoracic surgery (cardiothoracic vascular surgery) providers in Arkansas.
See all thoracic surgery (cardiothoracic vascular surgery) providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 21 | $9,751 |
| Doxycycline Hyclate | 60 | $834 |
| Gentamicin Sulfate | 14 | $747 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $220 |
| Amoxicillin | 23 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,567 | $9,75121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 48 thoracic surgery (cardiothoracic vascular surgery) providers in Arkansas.
Other thoracic surgery (cardiothoracic vascular surgery) in Little Rock
- Bassam ShukrallahLittle Rock$325K
- Pouya HemmatiLittle Rock$168K
- Katy MarinoLittle Rock$99K
- Charles ColeLittle Rock$23K
- Karol MudyLittle Rock$21K
- Jason MuesseLittle Rock$20K
- Kristofer FreelandLittle Rock$16K
- Michael NolenLittle Rock$15K
- John StreitmanLittle Rock$14K
- John RansomLittle Rock$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.